ReviewBone marrow transplantation2019
Update of the "Beijing Protocol" haplo-identical hematopoietic stem cell transplantation.
Review in Bone marrow transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07588360 (Haploidentical Combined With Cord Blood Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Haploidentical Combined With Cord Blood Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes: A Prospective, Multicenter Clinical Study
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Mesenchymal stromal cells as prophylaxis for graft-versus-host disease in haplo-identical hematopoietic stem cell transplantation recipients with severe aplastic anemia?-a systematic review and meta-analysis.Stem cell research & therapy · 2021Pooled it
- Prognosis and risk factors for central nervous system relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.Annals of hematology · 2021Trial
- Sequential Transplantation of Haploidentical Stem Cell and Unrelated Cord Blood With Using ATG/PTCY Increases Survival of Relapsed/Refractory Hematologic Malignancies.Frontiers in immunology · 2021Trial
- Cerebrospinal fluid profile associated with the incidence and outcomes of patients with chronic graft-versus-host disease after haploidentical hematopoietic stem cell transplantation.Blood science (Baltimore, Md.) · 2025Article
- Haploidentical Hematopoietic Stem Cell Transplantation for AML Patients with Persistent Molecular MRD.Current medical science · 2025Article
- Haploidentical hematopoietic stem cell transplantation for hematologic malignancies: a novel conditioning regimen with anti-T lymphocyte immunoglobulin instead of anti-thymocyte globulin for in vivo T cell depletion.Bone marrow transplantation · 2025Article
- Efficacy and safety of ruxolitinib combined with steroids for first-line treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: a single-center, real-world experience.Frontiers in immunology · 2025Article
- [Survival after hematopoietic stem cell transplantation with identical and haploidentical donors].Revista medica del Instituto Mexicano del Seguro Social · 2024Observational
- Article
- Haploidentical HSCT in the Treatment of Pediatric Hematological Disorders.International journal of molecular sciences · 2024Review
- Real-world outcomes and prognostic factors among patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation.Annals of hematology · 2023Article
- Analysis of the benefit of gonadotropin-releasing hormone agonist treatment in premenopausal women undergoing hematopoietic cell transplantation.Scientific reports · 2023Article
- [Impact of immunosuppression intensified conditioning regimen for patients with strong positive pre-transplantation donor-specific anti-HLA antibodies (DSAs) undergoing haploidentical hematopoietic stem cell transplantation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
- Successful Haploidentical Hematopoietic Stem Cell Transplantation with Azacitidine and Venetoclax Maintenance Therapy for Acute Myeloid Leukemia withTurkish journal of haematology : official journal of Turkish Society of Haematology · 2023Article
- A BMP-2-triggered in vivo osteo-organoid for cell therapy.Science advances · 2023Article
- Refractory cytomegalovirus infections in Chinese patients receiving allogeneic hematopoietic cell transplantation: a review of the literature.Frontiers in immunology · 2023Review
- Impact of Early Natural Killer Cell Reconstitution on the Outcomes of T Cell-Replete Allogeneic Hematopoietic Stem Cell Transplantation.Journal of inflammation research · 2023Article
- Current status and prospects of hematopoietic stem cell transplantation in China.Chinese medical journal · 2022Review
- Comparable Outcomes in Acquired Severe Aplastic Anemia Patients With Haploidentical Donor or Matched Related Donor Transplantation: A Retrospective Single-Center Experience.Frontiers in medicine · 2021Article
- G-CSF-Primed Peripheral Blood Stem Cell Haploidentical Transplantation Could Achieve Satisfactory Clinical Outcomes for Acute Leukemia Patients in the First Complete Remission: A Registered Study.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As one of the three successful approaches for haplo-identical stem cell transplantation (haplo-SCT) in recent decades, "Beijing protocol" was based on immune tolerance induced by granulocyte colony-stimulating factor plus anti-thymocyte globulin, which included individualized conditioning regimens, novel donor selection algorithm, and risk-directed strategies for GvHD and relapse, etc. Haplo-HSCT following "Beijing protocol" demonstrated similar efficacy to HLA-matched SCT, which has become the predominant strategy for allogeneic SCT in China as well as inspiration for refinement of global practice. This review will focus on recent progressions and prospective of this approach in (1) the indications from hematological malignancies to non-malignant diseases; (2) microenvironment for hematopoietic recovery; and (3) improving T cells function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.